Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02152371 · ClinicalTrials.gov registry record · Phase 3
A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 300
- Enrollment target
NCT02152371 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 300 participants.
The verdict
NCT02152371, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 300 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate the use of the study drug known as dulaglutide in participants with type II diabetes who are taking once-daily insulin glargine. The study will last about 31 weeks for each participant.
Interventions
- DRUG Placebo
- DRUG Metformin
- DRUG Dulaglutide
- DRUG Insulin Glargine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02152371
The ClinicalTrials.gov registry entry for NCT02152371 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02152371 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02152371 about?
NCT02152371 is a clinical study titled "A Study of Dulaglutide (LY2189265) in Participants With Type II Diabetes". The main purpose of this study is to evaluate the use of the study drug known as dulaglutide in participants with type II diabetes who are taking once-daily insulin glargine. The study will last about 31 weeks for each participant.
What is the current status of trial NCT02152371?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 300 participants. The study started on 2014-05. Estimated completion is 2015-10.
What interventions are being tested in trial NCT02152371?
The interventions under investigation include: Placebo (DRUG), Metformin (DRUG), Dulaglutide (DRUG), Insulin Glargine (DRUG).
Who is sponsoring clinical trial NCT02152371?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.